Sabada Dube
YOU?
Author Swipe
View article: Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals
Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals Open
Many immunocompromised individuals mount inadequate immune responses following COVID-19 vaccination, thus relying on other social distancing behaviours, particularly shielding, for protection, impacting their quality of life. However, litt…
View article: COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review Open
From the beginning of the pandemic, people with cancer have experienced a high burden from COVID-19 compared with the general population, both in terms of severe COVID-19-related outcomes and reduced health-related quality of life and ment…
View article: Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study
Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study Open
Beyond three years since the start of the COVID-19 pandemic, immunocompromised individuals remain disproportionately impacted from COVID-19 despite increased vaccination. These findings highlight a persistent need for additional COVID-19 i…
View article: P-2006. Individuals on Immunosuppressive or Immunomodulatory Therapies Remain at Increased Risk of COVID-19 Hospitalization, Despite Vaccination: Findings from INFORM, a Retrospective Health Database Study in England
P-2006. Individuals on Immunosuppressive or Immunomodulatory Therapies Remain at Increased Risk of COVID-19 Hospitalization, Despite Vaccination: Findings from INFORM, a Retrospective Health Database Study in England Open
Background Use of immunosuppressive or immunomodulatory therapies (IITs) may be a risk factor for severe COVID-19 outcomes. The INFORM (INvestigation oF cOvid-19 Risk among iMmunocompromised populations) study (ISRCTN53375662) uses routine…
View article: P-1989. COVID-19 Mortality Among Immunocompromised Individuals is Consistently High Compared with Non-Immunocompromised Individuals: Results of the INFORM Study 2022, England
P-1989. COVID-19 Mortality Among Immunocompromised Individuals is Consistently High Compared with Non-Immunocompromised Individuals: Results of the INFORM Study 2022, England Open
Background The INFORM study showed the disproportionate risk of COVID-19 hospitalization and mortality among immunocompromised (IC) versus non-immunocompromised (non-IC) individuals. This analysis aimed to describe the relationship between…
View article: Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period Open
Our results suggest that AZD7442 300 mg reduced COVID-19 hospitalizations among immunocompromised individuals; however, the findings are limited by a lack of sufficient events to produce conclusive results.
View article: Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals Open
View article: Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab
Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab Open
Background Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear. Additionally, the impact of pul…
View article: Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747]
Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] Open
[This corrects the article DOI: 10.1016/j.lanepe.2023.100747.].
View article: Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups
Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups Open
These results show AZD7442 uptake among the eligible population of Israel in 2022 was relatively low, at 14.8%. Uptake was generally higher among immunocompromised individuals who may be perceived to be frail or at highest risk of COVID-19…
View article: 1096. Fully Vaccinated Individuals with Immunocompromised Conditions (IC) are Still at Increased Risk of Severe COVID-19 Outcomes From the Omicron Variant: Initial Results From INFORM, a Retrospective Health Database Observational Study in England
1096. Fully Vaccinated Individuals with Immunocompromised Conditions (IC) are Still at Increased Risk of Severe COVID-19 Outcomes From the Omicron Variant: Initial Results From INFORM, a Retrospective Health Database Observational Study in England Open
Background UK vaccination programs have reduced COVID-19–related hospitalizations and deaths in the overall population, yet vaccinated individuals with immunocompromised conditions (IC) are still at high risk of severe COVID-19 outcomes. C…
View article: 398. Increased Risk of Severe COVID-19 Outcomes Across all Groups of Individuals with Hematological Malignancies, Solid Tumors, and Solid Organ Transplants Compared with the General Population: Initial Results from INFORM, a Retrospective Health Database Observational Study in England
398. Increased Risk of Severe COVID-19 Outcomes Across all Groups of Individuals with Hematological Malignancies, Solid Tumors, and Solid Organ Transplants Compared with the General Population: Initial Results from INFORM, a Retrospective Health Database Observational Study in England Open
Background Despite COVID-19 vaccination, individuals who are immunocompromised due to underlying conditions, such as cancer and organ transplant, are at a greater risk of severe COVID-19 outcomes compared with the general population that i…
View article: 1095. Increased Risk of COVID-19 Hospitalization and Death in Vaccinated Patients with End-Stage Renal Disease (ESRD) and Dialysis: Initial Results from INFORM, a Retrospective Health Database Observational Study in England
1095. Increased Risk of COVID-19 Hospitalization and Death in Vaccinated Patients with End-Stage Renal Disease (ESRD) and Dialysis: Initial Results from INFORM, a Retrospective Health Database Observational Study in England Open
Background Individuals with immunocompromised conditions (IC) have a higher risk of COVID-19 morbidity and death despite vaccination. Though patients (pts) with ESRD are considered immunocompromised and have a weaker antibody response to C…
View article: Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study Open
This study was funded by AstraZeneca UK.
View article: Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use
Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use Open
View article: 180 Real-world treatment patterns and outcomes with first-line maintenance olaparib for BRCAm advanced ovarian cancer: a pan-European study (OVAL-1)
180 Real-world treatment patterns and outcomes with first-line maintenance olaparib for BRCAm advanced ovarian cancer: a pan-European study (OVAL-1) Open
Introduction/Background* Standard therapy for advanced ovarian cancer (OC) includes radical debulking surgery followed by first-line platinum-based chemotherapy, although neo-adjuvant chemotherapy can be used. Most women with newly diagnos…
View article: The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe
The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe Open
View article: Evolution of <i>RAS</i> Testing Over Time: Factors Influencing Mutation Rates in Metastatic Colorectal Cancer Patients
Evolution of <i>RAS</i> Testing Over Time: Factors Influencing Mutation Rates in Metastatic Colorectal Cancer Patients Open
\n Contains fulltext :\n 219102.pdf (Publisher’s version ) (Open Access)\n